Objective: To compare the efficacy of Oral Ivermectin with Permethrin 1% Shampoo in the treatment of Pediculosis Capitis Study Design: Randomized controlled trial Setting & Study duration: This study was conducted at the Department of Dermatology, Bolan Medical College/ Sandeman Provincial Hospital, Quetta from December 24, 2016 to June 23, 2017 (6 months) Materials and Methods: All children of either gender having age 5 and above weight more than 15 kg presented with head-lice infestation confirmed by combing the wet hair with a fine-toothed detection comb were enrolled. All patients were randomly allocated into two groups. Patients in group A received oral Ivermectin in dose of 200mcg/kg while patients in group B received application of 1% Permethrin Shampoo. They were called after one week and they received second dose of oral Ivermectin in same dose of 200mcg/kg and application of Permethrin 1% Shampoo and re-evaluated after one week. Treatment was considered effective by absence of live lice by day 15 of treatment. Data was analyzed in SPSS version 17.Mean age of the patient in the sample was calculated. Male to female ratio was determined in the sample. In both the groups, frequency of patients having no live louse in the head on 15th day was calculated. The frequency in both groups was compared by applying chi square test keeping p-value≤ 0.05. Results: Majority of the patients presented were females in both group, i.e. 20 (66.7%) and 23 (76.7%) respectively. Insignificant difference was observed in the mean age in between group (p- value 0.482). Efficacy was found significantly higher in oral Ivermectin group 26 (86.7%) as compared to 1% Permethrin Shampoo. (p-value <0.001). Conclusion: The efficacy of oral Ivermectin group was considerably higher as compared to 1% Permethrin Shampoo in our cohort.

Objective: The main objective of this study is to determine the efficacy of metformin therapy on clinical and hormonal indices of patients with polycystic ovary syndrome. Study Design: Randomized control trial Place and Duration: Study was conducted at Obstetrics & Gynaecology department of Northwest General Hospital and Research Center, Peshawar and Mian Rashid Hussain Shaheed Memorial Hospital, Pabbi for duration of nine months from March 2020 to November 2020. Methods: Total 100 patients of polycystic ovary syndrome were presented in this study. Patients were aged between 18 to 45years. Patients detailed demographics including age, body mass index and socio-economicstatus were recorded after taking informed written consent. Patients were divided into 2-groups, group I had 50 patients and received metformin (500 mg) three times a day and group II had 50 patients and received pioglitazone (30 mg) three times a day for 3months.Clinical (body weight, blood pressure (BP), and body mass index) and indices fasting blood sugar (FBS), serum triglyceride (TG), cholesterol, low-density lipoprotein, high-density lipoprotein, insulin, testosterone, and dehydroepiandrosterone (DHEA) were measured before and after therapy. Complete data was analyzed by SPSS 22.0 version. Results: Mean age of the patients in group I was 29.18 ± 2.25 years with mean BMI 26.14 ± 8.86 kg/m2 and in group II mean age was 29.8 ± 2.52 years with mean BMI 27.64 ± 7.68 kg/m2.Significantly decrease in blood pressure (systolic 105.41±8.57, diastolic 67.19±8.9), hair loss 20 (40%),oligomenorrhea 23 (46%), body weight 74.45±9.72, waist circumference and dehydroepiandrosterone (DHEA) 2.35±0.67 and as compared to group II. Only triglycerides gave results of reduction in group II 115.39±64.11. Among both groups serum insulin, acne, menstrual disturbance and fasting blood sugar were controlled after treatment. Conclusion: We concluded in this study that use of metformin in patients with polycystic ovary syndrome resulted in to decrease clinical body weight, blood pressure (BP), body mass index and hormonal indices with reduction of serum insulin, acne, menstrual disturbance and fasting blood sugar but pioglitazone was an alternative effective and reliable method in PCOS patients. Keywords: Polycystic ovary syndrome, Insulin resistance, Metformin, Pioglitazone